Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants.

[1]  A. Parkhomenko,et al.  Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). , 2013, Journal of the American College of Cardiology.

[2]  H. Nar,et al.  A specific antidote for dabigatran: functional and structural characterization. , 2013, Blood.

[3]  S. Yusuf,et al.  Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding , 2013, Circulation.

[4]  Frank Akwaa,et al.  Treatment of Bleeding Complications When Using Oral Anticoagulants for Prevention of Strokes , 2013, Current Treatment Options in Cardiovascular Medicine.

[5]  A. Parkhomenko,et al.  Rivaroxaban in Patients Stabilized after a ST-Elevation Myocardial Infarction: Results from the ATLAS ACS 2-TIMI 51 Trial. , 2013 .

[6]  P. Conley,et al.  A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa , 2013, Nature Medicine.

[7]  Wei Zhou,et al.  Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With Rivaroxaban , 2013, Stroke.

[8]  T. Wilkinson,et al.  Warfarin‐related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates , 2013, Internal medicine journal.

[9]  G. Lip,et al.  General mechanisms of coagulation and targets of anticoagulants (Section I) , 2013, Thrombosis and Haemostasis.

[10]  S. Goldhaber,et al.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. , 2013, The New England journal of medicine.

[11]  G. Raskob,et al.  Apixaban for extended treatment of venous thromboembolism. , 2013, The New England journal of medicine.

[12]  D. Siegal,et al.  Reversal of novel oral anticoagulants in patients with major bleeding , 2013, Journal of Thrombosis and Thrombolysis.

[13]  T. Slowinski,et al.  Effective elimination of dabigatran by haemodialysis , 2013, Thrombosis and Haemostasis.

[14]  A. Mebazaa,et al.  Rivaroxaban for thromboprophylaxis in acutely ill medical patients. , 2013, The New England journal of medicine.

[15]  T. Gomes,et al.  Rates of hemorrhage during warfarin therapy for atrial fibrillation , 2013, Canadian Medical Association Journal.

[16]  J. Douketis,et al.  Management of Bleeding in Patients Receiving Conventional or New Anticoagulants , 2012, Drugs.

[17]  C. Lynch,et al.  Positive Outcome After Intentional Overdose of Dabigatran , 2012, Journal of Medical Toxicology.

[18]  M. Díaz-Ricart,et al.  Coagulation Factor Concentrates Restore Alterations in Hemostasis Induced by a High Dose of Apixaban: Studies in Vitro with Circulating Human Blood. , 2012 .

[19]  J. Eikelboom,et al.  Periprocedural management and approach to bleeding in patients taking dabigatran. , 2012, Circulation.

[20]  S. Yusuf,et al.  Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries: An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial , 2012, Circulation.

[21]  D. Jennings,et al.  Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[22]  K. Butcher,et al.  Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage Despite Anticoagulation Reversal , 2012, Stroke.

[23]  S. Yusuf,et al.  Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial , 2012, Stroke.

[24]  J. Cracowski,et al.  Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban , 2012, Thrombosis and Haemostasis.

[25]  J. Douketis,et al.  Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors , 2012, American journal of hematology.

[26]  E. Perzborn,et al.  Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin , 2012, Thrombosis and Haemostasis.

[27]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[28]  I. Pragst,et al.  Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits , 2012 .

[29]  Stanley Nattel,et al.  Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. , 2012, The Canadian journal of cardiology.

[30]  M. Feuring,et al.  Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran , 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[31]  Michael T. Mullen,et al.  Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists. , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[32]  Jason C. Fish,et al.  Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[33]  R. Whitlock,et al.  Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[34]  W. Ageno,et al.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[35]  F. Dentali,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[36]  Paul Burton,et al.  Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[37]  C. Samama,et al.  Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model , 2012, Anesthesiology.

[38]  M. Samama,et al.  Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls , 2011, Thrombosis and Haemostasis.

[39]  S. Goldhaber,et al.  Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. , 2011, The New England journal of medicine.

[40]  S. Goldhaber,et al.  A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II) , 2011 .

[41]  A. Clemens,et al.  The Successful Reversal of Dabigatran-Induced Bleeding by Coagulation Factor Concentrates in a Rat Tail Bleeding Model Do Not Correlate with Ex Vivo Markers of Anticoagulation , 2011 .

[42]  P. Kamphuisen,et al.  Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects , 2011, Circulation.

[43]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[44]  Deepak L. Bhatt,et al.  Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.

[45]  G. Lip,et al.  Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[46]  B. Eriksson,et al.  Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) , 2011, Thrombosis and Haemostasis.

[47]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[48]  G. Raskob,et al.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. , 2010, The New England journal of medicine.

[49]  A. Shenker,et al.  Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay , 2010, Thrombosis and Haemostasis.

[50]  J. Douketis.  Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. , 2010, Current pharmaceutical design.

[51]  W. Ageno,et al.  Twelve‐month outcomes and predictors of very stable INR control in prevalent warfarin users , 2010, Journal of thrombosis and haemostasis : JTH.

[52]  K. Rathgen,et al.  Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate , 2010, Clinical pharmacokinetics.

[53]  M. Feuring,et al.  Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity , 2010, Thrombosis and Haemostasis.

[54]  G. Raskob,et al.  Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial , 2010, The Lancet.

[55]  R. Gascoyne,et al.  Lymphoma stem cells: enough evidence to support their existence? , 2010, Haematologica.

[56]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[57]  G. Raskob,et al.  Apixaban or enoxaparin for thromboprophylaxis after knee replacement. , 2009, The New England journal of medicine.

[58]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[59]  A. Clemens,et al.  Adsorption of Dabigatran Etexilate in Water or Dabigatran in Pooled Human Plasma by Activated Charcoal in Vitro. , 2009 .

[60]  W. Ageno,et al.  Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. , 2009, Blood.

[61]  M. Gent,et al.  Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial , 2009, The Lancet.

[62]  A. Gruber,et al.  Potential of Activated Prothrombin Complex Concentrate and Activated Factor VII to Reverse the Anticoagulant Effects of Rivaroxaban in Primates , 2008 .

[63]  S. Yusuf,et al.  Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range , 2008, Circulation.

[64]  E. Wijdicks,et al.  Predictors of outcome in warfarin-related intracerebral hemorrhage. , 2008, Archives of neurology.

[65]  Bengt I Eriksson,et al.  Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial , 2008, The Lancet.

[66]  B. Eriksson,et al.  Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. , 2008, The New England journal of medicine.

[67]  W. Ageno,et al.  Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. , 2008, The New England journal of medicine.

[68]  S. Frostick,et al.  Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial , 2007, Journal of thrombosis and haemostasis : JTH.

[69]  S. Frostick,et al.  Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial , 2007, The Lancet.

[70]  D. Singer,et al.  Death and disability from warfarin-associated intracranial and extracranial hemorrhages. , 2007, The American journal of medicine.

[71]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease. , 2007, European heart journal.

[72]  M. Hartmann,et al.  Hematoma Growth and Outcome in Treated Neurocritical Care Patients With Intracerebral Hemorrhage Related to Oral Anticoagulant Therapy: Comparison of Acute Treatment Strategies Using Vitamin K, Fresh Frozen Plasma, and Prothrombin Complex Concentrates , 2006, Stroke.

[73]  P. O'Malley,et al.  Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. , 2006, Archives of internal medicine.

[74]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[75]  E. Hylek,et al.  Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.

[76]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[77]  P. Akins,et al.  Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. , 2014, World neurosurgery.

[78]  W. Ageno,et al.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis , 2012 .

[79]  G. Raskob,et al.  Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. , 2009, The Journal of arthroplasty.

[80]  E. Perzborn,et al.  Prothrombin Complex Concentrate Reverses the Effects of High-Dose Rivaroxaban in Rats , 2009 .